USE OF XENON AS NEUROPROTECTANT IN A NEONATAL SUBJECT
The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
1 - 93 . (canceled)
94 . A method of treating, preventing, and/or alleviating anesthetic-induced neurological deficits in a neonatal subject, the method comprising administering a therapeutically effective amount of xenon to said subject.
95 . The method of claim 94 , wherein the neurological deficit is associated with neuronal apoptosis, neuronal necrosis, or neuronal injury.
96 . The method of claim 94 , wherein the neurological deficit is neurodegeneration.
97 . The method of claim 94 , wherein the neurological deficit is a learning, memory, neuromotor, neurocognitive or psychocognitive deficit.
98 . The method of claim 94 , wherein the anesthetic is a GABAergic agent.
99 . The method of claim 94 , wherein the anesthetic is isoflurane, sevoflurant or desflurane.
100 . The method of claim 94 , wherein the anesthetic is isoflurane, the neurological deficit is neuronal injury, and the method further comprises administering isoflurane to the subject.
101 . The method of claim 94 , wherein the anesthetic is sevoflurane, the neurological deficit is associated with neuronal injury, and the method further comprising administering sevoflurane.
102 . The method of claim 94 , wherein the anesthetic is desflurane, the neurological deficit is associated with neuronal injury, and the method further comprises administering desflurane.
103 . The method of claim 94 , wherein the xenon is administered via perfusion.
104 . The method of claim 94 , wherein the xenon is in gaseous form.
105 . The method of claim 94 , wherein the xenon is administered via inhalation.
106 . A method of providing anesthesia, neuroprotection, and/or analgesia to a neonatal subject, said method comprising administering xenon in combination with another anesthesia, wherein the amount of xenon is sufficient to alleviate and/or prevent anesthesia-induced neuronal injury.
107 . The method of claim 106 , wherein the anesthetic is isoflurane, sevoflurane or desflurane.
108 . The method of claim 106 , wherein the xenon is in gaseous form.
109 . The method of claim 106 , wherein xenon is administered via inhalation.
110 . The method of claim 106 , wherein the xenon is administered via perfusion.
111 . The method of claim 106 , further comprising administering a GABAergic agent.
112 . A method of protecting against hypoxic injury comprising:
administering xenon in combination with an anesthetic.
113 . The method of claim 112 , wherein the anesthetic is sevoflurane, isoflurane or desflurane.
114 . The method of claim 112 , wherein the anesthetic is sevoflurane and the xenon and the sevoflurane are administered prior to the hypoxic-ischaemic injury.
115 . The method of claim 112 , wherein the anesthetic is sevoflurane and the xexon and the sevoflurane are administered at least about two hours prior to the hypoxic-ischaemic injury.
116 . The method of claim 114 , wherein the xenon and the sevoflurane are administered from about 2 to about 24 hours prior to the hypoxic-ischaemic injury.
117 . The method of claim 112 , wherein the xenon and sevoflurane are administered to the mother prior to delivery, during delivery, prior to a cesarean section, during a cesarean section, or suitable combinations thereof.
118 . A method of treating, alleviating, and/or preventing neuronal necrosis in a subject, said method comprising administering a therapeutically effective amount of xenon to the patient.